In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Amneal Pharmaceuticals trades slightly above its PERT-weighted fair value, with valuation methods showing wide disparities, indicating mixed market sentiment. Low profitability and efficiency scores contrast with strong liquidity and high leverage, signaling financial vulnerability amid growth uncertainty. Monte Carlo analysis reveals high volatility and significant downside risk, highlighting substantial investment risk despite some upside scenarios.